Questions to ask before considering TB-500 for a dog

1. What exact molecule and formulation is being proposed?

Ask whether the discussion concerns full-length thymosin beta-4, a particular fragment, or a product sold under the TB-500 name. Confirm the amino-acid sequence, concentration, route, manufacturer or compounding pharmacy, and whether the formulation was independently verified.

A purity result does not by itself establish sterility, identity, stability, clinical effectiveness, or appropriate use in a dog.

2. What evidence exists for this dog’s condition?

Ask for controlled studies in dogs with the same diagnosis—not general statements about cell migration, wound repair, horses, rodents, or human research. Then ask whether outcomes were meaningful to daily life: comfortable walking, validated pain scores, return to function, or fewer complications.

If the evidence is preclinical or extrapolated, that uncertainty should be explicit.

3. What established options belong in the comparison?

The alternative is rarely “TB-500 or nothing.” Depending on the diagnosis, the comparison may include rest or activity modification, rehabilitation, weight management, an approved pain medication, anti-NGF therapy, PSGAG treatment, imaging, or surgery.

Ask what has already been diagnosed, what has been tried at an adequate dose and duration, and what could be missed by treating before completing the workup.

4. How would safety and benefit be monitored?

• Which baseline examination or laboratory tests are needed?
• What side effects or interactions are known, suspected, or unknown?
• Who should be contacted after hours?
• What measurable change would count as benefit?
• When would the plan be reassessed or stopped?
• How would an adverse event be documented and reported?